January 6, 2020 08:11 AM EST
Financing
R&D

The first biotech IPO of the new decade has land­ed — and of course it's an­oth­er can­cer drug de­vel­op­er

Jason Mast

Editor

The first biotech IPO of 2020 is here, and it’s for a com­pa­ny found­ed by two mar­quee names in on­col­o­gy.

Cam­bridge-based Black Di­a­mond Ther­a­peu­tics filed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

Rev­o­lu­tion Med­i­ci­nes' KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Ex­clu­sive: Can AI re­place an­i­mal test­ing? A new biotech launch­es to find out

France stops Val­neva's chikun­gun­ya vac­cine roll­out in over 65s af­ter safe­ty is­sue

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times